Back to BNP PARIBAS FINANCIAL MARKETS BNP PARIBAS FINANCIAL MARKETS

BCLIBCLI
4 quarters

Position history for BNP PARIBAS FINANCIAL MARKETSBNP PARIBAS FINANCIAL MARKETS's holdings in BrainStorm Cell Therapeutics In

No. BNP Paribas Financial Markets exited its BCLI (BrainStorm Cell Therapeutics in) position in Q3 2025. Its Q2 2025 13F listed 24 shares worth $27. BNP Paribas Financial Markets first reported BCLI in Q4 2024 and held it in 3 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$54

Total Shares Change

-24

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q3
Latest
Exited
0
-100.0%
$00.0%$0.70
0
2025-Q2
Unchanged
24
0.0%
$270.0%$1.06
0
2025-Q1
Unchanged
24
0.0%
$300.0%$1.19
0
2024-Q4
New
24
-
$540.0%$2.37
17

Other major holders of BCLI: VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used